The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

Abbott Laboratories (ABT) Q3 Earnings Report Preview: What To Look For

ABT Cover Image

Healthcare product and device company Abbott Laboratories (NYSE: ABT) will be reporting earnings this Wednesday morning. Here’s what investors should know.

Abbott Laboratories beat analysts’ revenue expectations by 0.9% last quarter, reporting revenues of $11.14 billion, up 7.4% year on year. It was a slower quarter for the company, with a significant miss of analysts’ EPS guidance for next quarter estimates and organic revenue in line with analysts’ estimates.

Is Abbott Laboratories a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Abbott Laboratories’s revenue to grow 7.2% year on year to $11.4 billion, improving from the 4.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.30 per share.

Abbott Laboratories Total Revenue

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Abbott Laboratories has missed Wall Street’s revenue estimates three times over the last two years.

Looking at Abbott Laboratories’s peers in the healthcare equipment and supplies segment, only Neogen has reported results so far. It beat analysts’ revenue estimates by 2.6%, posting year-on-year sales declines of 3.6%. The stock traded up 3.7% on the results.

Read our full analysis of Neogen’s earnings results here.

Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices up 1.4% on average over the last month. Abbott Laboratories’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $143.12 (compared to the current share price of $131.40).

P.S. While everyone's chasing Nvidia, we found a hidden AI semiconductor winner trading at a fraction of the price. See our #1 pick before Wall Street catches on.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
-1.43 (-0.67%)
AAPL  252.29
+4.84 (1.96%)
AMD  233.08
-1.48 (-0.63%)
BAC  51.28
+0.84 (1.67%)
GOOG  253.79
+1.91 (0.76%)
META  716.91
+4.84 (0.68%)
MSFT  513.58
+1.97 (0.39%)
NVDA  183.16
+1.35 (0.74%)
ORCL  291.31
-21.69 (-6.93%)
TSLA  439.31
+10.56 (2.46%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.